An evaluation of selumetinib for the treatment of neurofibromatosis type 1-associated symptomatic, inoperable plexiform neurofibromas

References

• Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet Part A. 2010 Feb;152a(2):327–332.
   PubMed Web of Science ®Google Scholar
• Korf BR. Neurofibromatosis. Handb Clin Neurol. 2013;111:333–340.
   PubMedGoogle Scholar
• Mautner VF, Asuagbor FA, Dombi E, et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol. 2008 Aug;10(4):593–598.
   PubMed Web of Science ®Google Scholar
• Staser K, Yang FC, Clapp DW. Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells. Curr Opin Hematol. 2010 Jul;17(4):287–293.
   PubMed Web of Science ®Google Scholar
• Gottfried ON, Viskochil DH, Couldwell WT. Neurofibromatosis type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neurosurg Focus. 2010 Jan;28(1):E8.
   PubMed Web of Science ®Google Scholar
• Korf BR. Plexiform neurofibromas. Am J Med Genet A. 1999 Mar 26;89(1):31–37. .
   PubMed Web of Science ®Google Scholar
• Dombi E, Solomon J, Gillespie AJ, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology. 2007 Feb 27;68(9):643–647. .
   PubMed Web of Science ®Google Scholar
• Azizi AA, Slavc I, Theisen BE, et al. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18 F]FDG-PET imaging. Is it of value in asymptomatic patients? Pediatr Blood Cancer. 2018 Jan;65(1):e26733.
   PubMed Web of Science ®Google Scholar
• Gutmann DH. Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma. J Child Neurol. 2008;23(10):1186–1194.
   PubMed Web of Science ®Google Scholar
• Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996 Feb;12(2):144–148.
   PubMed Web of Science ®Google Scholar
• Helfferich J, Nijmeijer R, Brouwer OF, et al. Neurofibromatosis type 1 associated low grade gliomas: a comparison with sporadic low grade gliomas. Crit Rev Oncol Hematol. 2016 Aug;104:30–41.
   PubMed Web of Science ®Google Scholar
• Ullrich NJ, Prabhu SP, Reddy AT, et al. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade Glioma: a neurofibromatosis clinical trials consortium study. Neuro Oncol. 2020 Apr 1;22:1527–1535.
   PubMed Web of Science ®Google Scholar
• Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019 Jul;20(7):1011–1022.
   PubMed Web of Science ®Google Scholar
• Dombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016 Dec 29;375(26):2550–2560. .
   PubMed Web of Science ®Google Scholar
• Gross AM, Wolters P, Baldwin A, et al. SPRINT: phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). J Clin oncol. 2018 May 20;36(15_suppl):10503. .
   Web of Science ®Google Scholar
• Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020 Apr 9;382(15):1430–1442. .
   PubMed Web of Science ®Google Scholar
• Caunt CJ, Sale MJ, Smith PD, et al. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015 Oct;15(10):577–592.
   PubMed Web of Science ®Google Scholar
• Needle MN, Cnaan A, Dattilo J, et al. Prognostic signs in the surgical management of plexiform neurofibroma: the Children’s Hospital of Philadelphia experience, 1974–1994. J Pediatr. 1997 Nov;131(5):678–682.
   PubMed Web of Science ®Google Scholar
• Jackson IT, Carbonnel A, Potparic Z, et al. Orbitotemporal neurofibromatosis: classification and treatment. Plast Reconstr Surg. 1993 Jul;92(1):1–11.
   PubMed Web of Science ®Google Scholar
• Robertson KA, Nalepa G, Yang FC, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 2012 Dec;13(12):1218–1224.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Babovic-Vuksanovic D, Dombi E, et al. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014 Sep;61(9):1598–1602.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Dombi E, Gillespie A, et al. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro Oncol. 2014 May;16(5):707–718.
   PubMed Web of Science ®Google Scholar
• Weiss B, Widemann BC, Wolters P, et al. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer. 2014 Jun;61(6):982–986.
   PubMed Web of Science ®Google Scholar
• Weiss B, Widemann BC, Wolters P, et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015 Apr;17(4):596–603.
   PubMed Web of Science ®Google Scholar
• Jakacki RI, Dombi E, Steinberg SM, et al. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro Oncol. 2017 Feb 1;19(2):289–297.
   PubMed Web of Science ®Google Scholar
• Fisher MJ, Shih CS, Rhodes SD, et al. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat Med. 2021 Jan;27(1):165–173.
   PubMed Web of Science ®Google Scholar
• Kim DW, Patel SP. Profile of selumetinib and its potential in the treatment of melanoma. Onco Targets Ther. 2014;7:1631–1639. .
   PubMed Web of Science ®Google Scholar
• Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res off J Am Assoc Cancer Res. 2007 Mar 1;13(5):1576–1583.
   PubMed Web of Science ®Google Scholar
• Dymond AW, Howes C, Pattison C, et al. Metabolism, excretion, and pharmacokinetics of selumetinib, an MEK1/2 inhibitor, in healthy adult male subjects. Clin Ther. 2016 Nov;38(11):2447–2458.
   PubMedGoogle Scholar
• Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008 May 1;26(13):2139–2146.
   PubMed Web of Science ®Google Scholar
• Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2010 Mar 1;16(5):1613–1623.
   PubMed Web of Science ®Google Scholar
• Leijen S, Soetekouw PM, Jeffry Evans TR, et al. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Dec;68(6):1619–1628.
   PubMed Web of Science ®Google Scholar
• Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020 Sep 24;383(13):1290
   Web of Science ®Google Scholar
• Seto T, Hirai F, Saka H, et al. Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. Jpn J Clin Oncol. 2018 Jan 1;48(1):31–42.
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. Jama. 2014 Jun 18;311(23):2397–2405.
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res off J Am Assoc Cancer Res. 2010 Mar 15;16(6):1924–1937.
   PubMed Web of Science ®Google Scholar
• Avery RA, Trimboli-Heidler C, Kilburn LB. Separation of outer retinal layers secondary to selumetinib. J Aapos. 2016 Jun;20(3):268–271.
   PubMed Web of Science ®Google Scholar
• Malone CF, Fromm JA, Maertens O, et al. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov. 2014 Sep;4(9):1062–1073.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Bendell JC, Papadopoulos KP, et al. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann Oncol. 2015 Jan;26(1):58–64.
   PubMed Web of Science ®Google Scholar